首页> 外文期刊>Toxicon: An International Journal Devoted to the Exchange of Knowledge on the Poisons Derived from Animals, Plants and Microorganisms >Leucurogin, a new recombinant disintegrin cloned from Bothrops leucurus (white-tailed-jararaca) with potent activity upon platelet aggregation and tumor growth
【24h】

Leucurogin, a new recombinant disintegrin cloned from Bothrops leucurus (white-tailed-jararaca) with potent activity upon platelet aggregation and tumor growth

机译:Leucurogin,一种新的重组disintegrin,从Bothrops leucurus(白尾jararaca)克隆而来,对血小板聚集和肿瘤生长具有有效活性

获取原文
获取原文并翻译 | 示例
           

摘要

Disintegrins and disintegrins-like proteins are able to inhibit platelet aggregation and integrin-mediated cell adhesion. The aim of this study was to produce one disintegrin-like cloned from Bothrops leucurus venom gland and to characterize it regarding biological activity. The recombinant protein was purified by one step procedure involving anion-exchange chromatography (DEAE-cellulose) and presented a molecular mass of 10.4 kDa. The purified protein was able to inhibit platelet aggregation induced by collagen (IC50 = 0.65 mu M) and to inhibit growth of Ehrlich tumor implanted in mice by more than 50% after 7 days administration of 10 mu g/day. No effects were observed upon adenosine 5'diphosphate (ADP)-and arachidonic acid (AA)-induced platelet aggregation. The recombinant protein was recognized by an antibody specific for jararhagin one metalloproteinase isolated from Bothrops jararaca venom, and therefore it was named leucurogin. Anti-angiogenesis effect of leucurogin was evaluated by the sponge implant model. After 7 days administration leucurogin inhibited, in a dose dependent way, the vascularization process in the sponge. Leucurogin represents a new biotechnological tool to understand biological processes where disintegrins-like are involved and may help to characterize integrins that can be involved in development and progression of malignant cells
机译:整合素和整合素样蛋白能够抑制血小板聚集和整合素介导的细胞粘附。这项研究的目的是生产一种从Bothrops leucurus蛇毒腺中克隆得到的disintegrin样,并对其生物学活性进行表征。通过涉及阴离子交换色谱法(DEAE-纤维素)的一步步骤纯化重组蛋白,其分子量为10.4kDa。纯化的蛋白质在施用10μg/天的7天后,能够抑制胶原蛋白诱导的血小板凝集(IC50 = 0.65μM),并抑制植入小鼠的Ehrlich肿瘤的生长超过50%。腺苷5'二磷酸(ADP)和花生四烯酸(AA)诱导的血小板聚集没有观察到影响。重组蛋白被一种对jararhagin特异的抗体所识别,该抗体是一种从Bothrops jararaca毒液中分离出的金属蛋白酶,因此被称为亮氨酸。用海绵植入物模型评估亮氨酸的抗血管生成作用。在给药7天后,亮白细胞素以剂量依赖性的方式抑制了海绵中的血管形成过程。 Leucurogin代表一种新的生物技术工具,可用于理解涉及整合素的类生物过程,并可能有助于表征可能参与恶性细胞发育和发展的整合素

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号